Michael A. Pisetsky, serving as Senior Vice President of Operations & Administration and Chief Legal Officer for SI-BONE, Inc. (NASDAQ:SIBN), completed a transaction involving the sale of 3,134 shares of the company's common stock on July 2, 2026. The aggregate value of these shares reached $52,375. The stock price has subsequently climbed to $17.68, reflecting a 1-week return of 1.36%. Market analysis suggests SI-BONE may be trading above its intrinsic Fair Value, yet the firm maintains a robust financial position with cash reserves exceeding its debt load.
The executed sales occurred at prices ranging from $16.6992 to $16.86 per share. These dispositions were strictly undertaken to satisfy tax withholding obligations associated with the vesting of restricted stock units. Consequently, these transactions do not indicate discretionary trading activity by Mr. Pisetsky. Following the completion of these sales, Mr. Pisetsky directly holds 277,375 shares of SI-BONE common stock. This total includes 137,587 shares issuable upon the settlement of restricted stock units, where each unit represents a contingent right to receive one share of the company's common stock.
The medical device company maintains a strong current ratio of 9.99 and posted revenue of $206 million with 17% growth in the last twelve months. In other recent news, SI-BONE, Inc. reported its first-quarter 2026 financial results, highlighting a strong performance with a narrower-than-expected net loss and significant revenue growth. The company posted an earnings per share (EPS) of -$0.10, exceeding the forecasted -$0.19, while revenue came in at $52.6 million, slightly below the projected $52.85 million. Truist Securities responded to these results by lowering its price target for SI-BONE from $20 to $18, although it maintained a Buy rating. The firm noted the company's first-quarter revenue and earnings beat and acknowledged the raised revenue and gross margin guidance. In addition, SI-BONE announced an amendment to its office lease agreement, extending the lease for its headquarters in Santa Clara, California, until August 31, 2026, with an option to extend for another month. The company also reported the results of its annual meeting, where shareholders elected Jeffrey W. Dunn and John G. Freund, M.D. as directors. These developments reflect ongoing strategic and operational adjustments by SI-BONE.